...
首页> 外文期刊>Cytotechnology >LPS administration increases CD11b+ c-Fms+ CD14+ cell population that possesses osteoclast differentiation potential in mice
【24h】

LPS administration increases CD11b+ c-Fms+ CD14+ cell population that possesses osteoclast differentiation potential in mice

机译:LPS给药可增加具有小鼠破骨细胞分化潜能的CD11b + c-Fms + CD14 +细胞群

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Osteoclasts are multinucleated giant cells that originate from a monocyte/macrophage lineage, and are involved in the inflammatory bone destruction accompanied by periodontitis. Recent studies have shown that osteoclast precursors reside not only in the bone marrow, but also in the peripheral blood and spleen, though the precise characteristics of each precursor have not been analyzed. We hypothesized that the number of osteoclast precursors in those tissues may increase under pathological conditions and contribute to osteoclast formation in vivo in a mouse model. To test this hypothesis, we attempted to identify cell populations that possess osteoclast differentiation potential in the bone marrow, spleen, and blood by analyzing macrophage/monocyte-related cell surface markers such as CD11b, CD14, and colony-stimulating factor-1 receptor (c-Fms). In the bone marrow, the CD11b? cell population, but not the CD11b+ cell population, differentiated into osteoclasts in the presence of receptor activator of nuclear factor-κB ligand and macrophage colony-stimulating factor. On the other hand, in the spleen and blood, CD11b+ cells differentiated into osteoclasts. Interestingly, lipopolysaccharide (LPS) administration to the mice dramatically increased the proportion of CD11b+ c-Fms+ CD14+ cells, which differentiated into osteoclasts, in the bone marrow and spleen. These results suggest that LPS administration increases the proportion of a distinct cell population expressing CD11b+, c-Fms+, and CD14+ in the bone marrow and spleen. Thus, these cell populations are considered to contribute to the increase in osteoclast number during inflammatory bone destruction such as periodontitis.
机译:破骨细胞是源自单核细胞/巨噬细胞谱系的多核巨细胞,并参与伴随牙周炎的炎性骨破坏。最近的研究表明破骨细胞前体不仅存在于骨髓中,而且还存在于外周血和脾脏中,尽管尚未分析每种前体的确切特征。我们假设这些组织中破骨细胞前体的数量在病理条件下可能会增加,并在小鼠模型中促进体内破骨细胞的形成。为了验证这一假设,我们尝试通过分析巨噬细胞/单核细胞相关的细胞表面标志物(例如CD11b,CD14和集落刺激因子1受体)来鉴定在骨髓,脾脏和血液中具有破骨细胞分化潜能的细胞群( c-Fms)。在骨髓中,CD11b?在存在核因子-κB配体和巨噬细胞集落刺激因子的受体激活剂的情况下,细胞群体(而非CD11b +细胞群体)分化为破骨细胞。另一方面,在脾脏和血液中,CD11b +细胞分化为破骨细胞。有趣的是,对小鼠施用脂多糖(LPS)可以显着增加骨髓和脾脏中分化为破骨细胞的CD11b + c-Fms + CD14 +细胞的比例。这些结果表明,LPS给药可增加骨髓和脾脏中表达CD11b +,c-Fms +和CD14 +的独特细胞群的比例。因此,这些细胞群被认为有助于在炎性骨破坏例如牙周炎期间增加破骨细胞数量。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号